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The prevalence of peripheral artery disease (PAD) is esti-
mated to be approximately 4.3% among U.S. adults older
than 40 years of age and close to 15% in those 75 years and
older (1). Patients with established PAD have a high
probability of atherosclerosis in other vascular beds (2) and
are at increased risk for myocardial infarction, stroke, and
death, as well as limb ischemic events that lead to peripheral
revascularization procedures and amputations (3). Data from
the international REACH (REduction of Atherothrombosis
for Continued Health) registry indicate that the annual risk
of cardiovascular death, myocardial infarction, and stroke in
patients with PAD can range from 4% to 5% for patients
with intermittent claudication to 8% for those with ischemic
amputations (3,4).See page 1529Interestingly, despite the increased risk and variability of
outcomes in patients with PAD, risk stratiﬁcation has
received relatively little attention in this population. This
contrasts sharply with patients who have established coro-
nary artery disease (CAD), where extensive investigation has
been performed to identify tools to enhance risk assessment.
Factors that have been associated with worse outcomes in
PAD patients include older age, smoking, diabetes, and
polyvascular disease (4). The most widely studied biomarker
for risk assessment in patients with PAD is high-sensitivity
C-reactive protein (hs-CRP). Previous studies have inves-
tigated hs-CRP in generally lower-risk PAD cohorts and
have reported increased cardiac event rates in patients with
higher hs-CRP levels, independent of measurements of
disease severity such as the ankle/brachial index (5,6).*Editorials published in the Journal of the American College of Cardiology reﬂect the
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Moreover, as this population already has an indication for
statin therapy and as hs-CRP correlates poorly with the
extent of CAD (7), there are no clear clinical implications
related to higher levels of this inﬂammatory biomarker.
Additionally, the utility of CRP in higher acuity patients in
the hospitalized setting is not clear. Several studies have also
assessed the prognostic utility of N-terminal pro–B-type
natriuretic peptide in patients with PAD (8,9), with in-
consistent results reported among studies.
Recently, there has been an interest in exploring the
role of pre-procedural measurements of cardiac troponin T
(cTnT) concentrations for risk stratiﬁcation in PAD patients
referred for surgical or endovascular revascularization
procedures. Although previous studies have clearly linked
post-operative troponin elevations with increased risk of
myocardial infarction and both short- and long-term mor-
tality (10), much less is known about troponin measure-
ments performed before the revascularization procedure.
Following publication of several favorable pilot studies
(11,12), Linnemann et al. (13) recently reported ﬁndings for
254 patients presenting with acute limb ischemia and
undergoing endovascular intervention at their institution in
2007 and noted that a cTnT concentration above the
detection range (0.01 ng/ml) at admission was indepen-
dently associated with in-hospital mortality and amputa-
tions. In this issue of the Journal, these authors extend their
ﬁndings to 1,065 patients with symptomatic PAD under-
going an endovascular intervention at a single institution
(14). cTnT was detectable (0.01 ng/ml) in more than 21%
of all patients. Predictably, these patients were older and had
a larger burden of comorbidities. One-year mortality rates in
patients with detectable cTnT levels were >8-fold higher
than in those with undetectable pre-operative cTnT levels,
even after adjusting for potential confounders in multivari-
able analyses. However, amputations were not different in
adjusted analyses between patients with and those without
cTnT elevation (14).
Because cTnT was measured only at admission in the
present study, it was not possible to determine whether
cTnT elevations were acute or chronic. In addition, the
cause of cTnT elevation is unclear. Although patients with
acute cardiac and noncardiac conditions that commonly lead
to troponin elevation (acute coronary syndromes, pulmonary
embolism, acute heart failure) were excluded from the
current study, troponin levels are frequently acutely elevated
among patients hospitalized with signiﬁcant medical or
surgical illnesses, even when one of the aforementioned
conditions is not present. Troponin elevation in such
patients may be caused by silent myocardial infarction (MI)
caused by plaque rupture (type 1 MI), by supply–demand
mismatch (type 2 MI), and by direct and indirect cardiac
injury from nonischemic mechanisms (15). In addition, it is
increasingly recognized that chronic troponin elevations are
commonly seen among patients with chronic coronary
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asymptomatic left ventricular hypertrophy and left ventric-
ular dysfunction (16,17). The troponin elevations detected
at the time of admission in the present study likely repre-
sented an admixture of several of these acute and chronic
conditions.
Several additional caveats to the present study merit
comment. First, the investigators used a standard cTnT
assay rather than a high-sensitivity troponin assay. With the
high-sensitivity cTnT assay, >90% of individuals with
chronic CAD or heart failure have measurable cTnT levels
(18,19). Studies in patients with chronic cardiovascular
disease show graded associations between troponin levels,
and death and heart failure outcomes, even at levels of cTnT
well below the detection range of standard assays (18,19).
One would expect an even higher proportion of PAD
patients would have detectable troponin levels with high-
sensitivity assays. The quantitative information provided by
the high-sensitivity troponin assays may allow more reﬁned
risk stratiﬁcation than is possible with the standard cTnT
assay used by Linnemann et al. (14) in the current study.
Second, the investigators do not report other important
cardiovascular outcomes such as heart failure. In previous
studies, even among patients with CAD, small elevations in
cTnT concentrations associated more robustly with heart
failure events than with ischemic events (19). Information
about heart failure would have been helpful because it might
have helped to explain the extremely high mortality rate in
the cTnT-positive patients (>30% at 1 year), despite only
a 4.1% incidence of MI.
How might the information reported by Linnemann et al.
(14) be of potential value for clinicians caring for PAD
patients undergoing endovascular procedures? PAD is
already considered a Class I indication for antiplatelet and
statin therapy (20), recommendations that are unlikely to
change based on troponin values. Unfortunately, the utili-
zation of evidence-based secondary prevention measures in
these patients remains suboptimal (21), and measures to
enhance adherence are urgently needed. In the current study,
although most patients were on aspirin at discharge, nearly
30% were discharged without a statin. Systems-based ap-
proaches to improve adherence with this measure at dis-
charge, as have been instituted for patients with acute
myocardial infarction, may be helpful (22).
Although myocardial infarction rates were increased
among patients with cTnT elevation in the current study,
randomized controlled trials have not demonstrated a beneﬁt
from coronary revascularization before surgical peripheral
arterial revascularization (23), or from pre-operative initia-
tion of beta-blocker therapy (24). It remains possible that
enhanced risk assessment using troponin measurements or
other risk stratiﬁcation tools may help to identify extremely
high-risk subgroups that derive beneﬁt from periproce-
dural beta-blockers or coronary revascularization, but this
hypothesis must be tested in adequately powered clinical
trials.Given the very high risk observed in patients with limb
ischemia when troponin elevation is detected, considera-
tion should be given to strategies that may prevent elevated
troponin levels in the ﬁrst place. Of course, this assumes
a causal relationship of troponin elevation and adverse
outcomes in this patient population, a hypothesis that remains
to be proven. Data from community-based cohorts have re-
ported associations of baseline HbA1c measurements and
ﬁtness levels with subsequent troponin elevation (25,26).
These observations suggest the possibility that enhanced
glycemic control and exercise may modify the cardiac injury
process and could prevent some of the troponin elevations
seen in this population.
The investigators are to be congratulated for performing
one of the largest risk stratiﬁcation studies in patients with
symptomatic PAD. Whereas previous studies have used
small and highly selected cohorts, the present study is large
and representative of the high-acuity patients frequently seen
by vascular medicine specialists. We hope these data will
help set the stage for future large and more comprehensive
studies to improve risk stratiﬁcation in this complex and
understudied population.
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